How many insider trades does FilingIQ track for SKYE?

FilingIQ tracks 122 Form 4 insider transactions for SKYE (Skye Bioscience, Inc.), covering filings from Dec 14, 2021 onwards. 45 of those were filed in the last 90 days.

Are SKYE insiders net buyers or net sellers?

Across the full Form 4 history for SKYE, 4 transactions (3%) were open-market purchases and 30 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does SKYE insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is SKYE in?

Skye Bioscience, Inc. (SKYE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $22.99M.

SKYE insider trading

Healthcare

Skye Bioscience, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

122

Last 90 days

Buys / sells

3% / 25%

Market cap

$22.99M

About Skye Bioscience, Inc.

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Company website: skyebioscience.com

SKYE insider activity at a glance

FilingIQ has scored 122 insider transactions for SKYE since Dec 14, 2021. The most recent filing in our index is dated Mar 31, 2026.

Across the full history, 4 open-market purchases and 30 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on SKYE insider trades is 53.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live SKYE trades on FilingIQ Raw filings on SEC EDGAR

Latest SKYE Form 4 filings

DHILLON PUNIT Chief Executive Officer

S Nov 18, 2024

ARSENAULT KAITLYN Chief Financial Officer

S Nov 18, 2024

DHILLON PUNIT Chief Executive Officer

P Aug 29, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for SKYE?: FilingIQ tracks 122 Form 4 insider transactions for SKYE (Skye Bioscience, Inc.), covering filings from Dec 14, 2021 onwards. 45 of those were filed in the last 90 days.
Are SKYE insiders net buyers or net sellers?: Across the full Form 4 history for SKYE, 4 transactions (3%) were open-market purchases and 30 (25%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does SKYE insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is SKYE in?: Skye Bioscience, Inc. (SKYE) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $22.99M.

Methodology & sources

Every SKYE insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.